Statistical Yearbook 2020
C. 5. Medicaments
Methodology
On the permanent address of the beneficiary of the prescription
5.1. Summary data of the subsidized turnover of pharmacies, 2020
5.2. Main data of the subsidized turnover of pharmacies by legal title, 2020
5.2.1. Development of the subsidized turnover of pharmacies within the subsidisation category linked to enhanced indication by sex and age group, 2020
5.2.2. Development of the subsidized turnover of pharmacies within the subsidisation category linked to lifted indication by sex and age group, 2020
5.2.3. Main data of the subsidized turnover within the normative subsidisation category, 2020
5.2.3.1. Development of the turnover subsidized up to 90%, 2020
5.2.3.2. Development of the turnover subsidized up to 85% by sex and age group, 2020
5.2.3.3. Development of the turnover subsidized up to 55% by sex and age group, 2020
5.2.3.4. Development of the turnover subsidized up to 50% by sex and age group, 2020
5.2.3.5. Development of the turnover subsidized up to 25% by sex and age group, 2020
5.2.3.6. Development of the turnover subsidized by fix amount by sex and age group, 2020
5.2.3.7. Development of the normative public health care by sex and age group, 2020
5.2.3.8. Development of the turnover subsidized of combined preparations by sex and age group, 2020
5.2.4. Development of the subsidized turnover of medicinal products within the subsidisation category linked to the equity legal title by sex and age group, 2020
5.3. Summary data of public health care (enhanced+lifted+normative) from subsidised turnover, 2020
On the basis of headquarters of the pharmacy redeeming the prescription
5.1. Summary data of the subsidized turnover of pharmacies, 2020
5.2. Main data of the subsidized turnover of pharmacies by legal title, 2020
5.2.1. Development of the subsidized turnover of pharmacies within the subsidisation category linked to enhanced indication by sex and age group, 2020
5.2.2. Development of the subsidized turnover of pharmacies within the subsidisation category linked to lifted indication by sex and age group, 2020
5.2.3. Main data of the subsidized turnover within the normative subsidisation category, 2020
5.2.3.1. Development of the turnover subsidized up to 85% by sex and age group, 2020
5.2.3.2. Development of the turnover subsidized up to 55% by sex and age group, 2020
5.2.3.3. Development of the turnover subsidized up to 50% by sex and age group, 2020
5.2.3.4. Development of the turnover subsidized up to 25% by sex and age group, 2020
5.2.3.5. Development of the turnover subsidized by fix amount by sex and age group, 2020
5.2.3.6. Development of the normative public health care by sex and age group, 2020
5.2.3.7. Development of the turnover subsidized of combined preparations by sex and age group, 2020
5.2.4. Development of the subsidized turnover of medicinal products within the subsidisation category linked to the equity legal title by sex and age group, 2020
5.3. Summary data of public health care (enhanced+lifted+normative) from subsidised turnover, 2020
NIHIFM --- Health, care
Sector Finance, Performance Improvement and Analysis Department / Statistical and Data Analysis Division, November 2021
NIHIFM --- Health, care